Medtech in a Minute: Stryker, Glaukos, and Elizabeth Holmes
It was a busy news week in medtech. Here's what you need to know to bring you up to speed quickly.
September 10, 2021
Stryker Hops Back on the M&A Train
Stryker acquired Gauss Surgical, developer of an AI-enabled platform for real-time monitoring of blood loss during surgery. The technology, Triton, has demonstrated improvements in maternal and surgical care through earlier recognition of hemorrhage leading to earlier intervention. The deal comes almost a year after Stryker closed on Wright Medical — one of its biggest acquisitions in recent history. In July, Stryker CEO Kevin Lobo mentioned that the company would be looking for tuck-in merger and aquisition (M&A) deals in the future.
Jury Tasked with Figuring Out Who Elizabeth Holmes Really Is
Is Elizabeth Holmes a hardworking executive manipulated by her ex-boyfriend and former chief operating officer, or is she a fraudster who pulled the wool over everyone's eyes? A 17-member jury heard two very different takes on Holmes during the opening statements of the former Theranos CEO's fraud trial.
Glaukos Seeks Approval for iStent Infinite
Glaukos is one step closer to bringing a new minimally invasive glaucoma surgery to the U.S. market. The company has submitted a supplemental PMA application to FDA for the iStent infiniteTrabecular Micro-Bypass System. The device is designed to reduce elevated intraocular pressure in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy.
And in case you missed our last Medtech in a Minute report...
Jury Selection Gets Underway in Holmes' Trial
Elizabeth Holmes is back in the mainstream news headlines this week as jury selection begins for her fraud trial. Opening statements are expected Sept. 8. The trial signals the beginning of the end of the industry's biggest scandal in recent history. Don't expect it to be a fast trial though, experts say it could take three months. Click the headline above for the full story. Or, for a quick visual of how Theranos' valuation skyrocketed and then plummeted, check out this graphic by News Editor Amanda Pedersen.
Rumor confirmed: Baxter to Acquire Hillrom for $12.4 billion
After weeks of speculation, Baxter confirmed this week that it has agreed to acquire Hillrom in a deal valued at $12.4 billion. The merger has the potential to expand access to Hillrom’s portfolio globally; broaden the presence of the combined companies across sites of care and accelerate and strengthen the combined organization’s digital transformation.
Zimmer Biomet Is Making Knees Smarter
FDA cleared Zimmer Biomet's Persona IQ smart knee implant, making it the first "smart" knee implant on the market for total knee replacement surgery. The device was previously identified by MD+DI as one of the 10 Most Anticipated New Medical Devices expected to reach the U.S. market by the end of the year.
About the Author
You May Also Like